Meningococcal vaccine in travelers

@article{WilderSmith2007MeningococcalVI,
  title={Meningococcal vaccine in travelers},
  author={Annelies Wilder-Smith},
  journal={Current Opinion in Infectious Diseases},
  year={2007},
  volume={20},
  pages={454–460}
}
  • A. Wilder-Smith
  • Published 1 October 2007
  • Medicine
  • Current Opinion in Infectious Diseases
Purpose of review New vaccines to prevent meningococcal disease have been licensed in recent years. It is therefore timely to discuss current vaccine strategies pertinent to international travelers in relation to the changing epidemiology. Recent findings Serogroup W135 achieved epidemic status in Africa in 2002, and then largely disappeared over a short time period. The year 2006 saw a marked epidemic rise in meningitis attack rates across the meningitis belt in Africa. This rise was mainly… Expand
Meningococcal disease: risk for international travellers and vaccine strategies.
TLDR
The tetravalent conjugate meningitis belt vaccine will be a leap forward in the control of meningococcal epidemics in affected countries because the duration of protection is longer and it eliminates the problem of immune hyporesponsiveness of serogroup C with repeated dosing. Expand
Protection of travellers against meningococcal disease: tetravalent conjugate vaccines offer new options *
TLDR
With tourism expanding to traditionally less-often visited areas, there is a growing need to develop an awareness of the risks and the risk to acquire meningococcal disease. Expand
Meningococcal vaccination for international travellers from Greece visiting developing countries.
TLDR
There is a need to improve meningococcal vaccine recommendations for travellers from Greece, particularly for high risk populations, such as VFRs, business travellers and those visiting sub-Saharan Africa especially during the dry season. Expand
Awareness of meningococcal disease among travelers from the United Kingdom to the meningitis belt in Africa.
TLDR
It is concluded that improved education of travelers may improve vaccine uptake before travel to the meningitis belt in Africa and knowledge of certain key symptoms or signs were statistically associated with high vaccine uptake. Expand
Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987-2013.
TLDR
Despite childhood routine vaccination with ACYW-135 polysaccharide vaccine, infants and young children remain at high risk for MD, which supports the introduction of conjugate meningococcal vaccine to the routine childhood vaccination schedule. Expand
Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
TLDR
Implementation of MCC vaccination in Tuscany was effective in preventing meningococcal C disease, confirming the effectiveness of the vaccine. Expand
Meningococcal vaccines: a neglected topic in travel medicine?
TLDR
Conjugate meningococcal vaccines have significant advantages over polysaccharide vaccines, and should be the preferred option for travelers. Expand
Vaccination of travelers: how far have we come and where are we going?
Vaccine recommendations are a prominent part of health preparations before international travel. We review progress made in the past decade regarding vaccines used primarily by persons traveling fromExpand
Invasive meningococcal disease and travel.
TLDR
The epidemiology of invasive meningococcal disease varies geographically and in time and the risk of acquiring the disease varies regionally, as well as with living conditions and behavior, so vaccination against serogroups A, C, W-135 and Y with novel conjugate vaccines may help protect individuals and reduce the spread of bacterial carriage and disease. Expand
The epidemiology of meningococcal disease and the impact of vaccines
TLDR
Development of vaccines for prevention of serogroups B disease in industrialized nations and serogroup A conjugate vaccines for Africa could lead to global control of meningococcal disease. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Meningococcal disease and travel.
TLDR
There should be a switch in recommendation from the bivalent (against A& C) to the quadrivalent vaccine for all travellers in view of increasing worldwide reports of Y and W135 meningococcal disease. Expand
A review of vaccine research and development: meningococcal disease.
TLDR
Widespread vaccination with Group C conjugate vaccines now in use in several European countries indicates that these vaccines are immunogenic, induce immunological memory, reduce colonization and provide herd immunity to the general population. Expand
Global Epidemiology of Meningococcal Disease and Vaccine Efficacy
  • A. Pollard
  • Medicine
  • The Pediatric infectious disease journal
  • 2004
TLDR
O Ongoing development of tetravalent A, C, Y, and W135 conjugate vaccines raises the hope that disease caused by these serogroups can be controlled in the near future. Expand
Control of epidemic group A meningococcal meningitis in Nepal.
TLDR
This experience demonstrates that it is possible, with appropriate surveillance efforts, to detect an evolving epidemic of meningococcal disease early in its course and to institute control measures in advance of the expected epidemic peak. Expand
Meningococcal Disease in Travelers: Vaccination Recommendations.
TLDR
For the usual traveler to endemic countries, the risk of infection abroad seems not to exceed the one at home, thus vaccination may be limited to high-risk groups, such as trekkers. Expand
Outbreaks of serogroup X meningococcal meningitis in Niger 1995–2000
TLDR
The increasing incidence of theserogroup X was not related to the decrease of serogroup A, but seemed cyclic, and evolved independently of the recurrence of both serogroups A and C. Expand
Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
TLDR
The safety and immunogenicity profile observed in this study of healthy adults enabled studies in children to be initiated using 25 microg dosage. Expand
A surveillance network for meningococcal disease in Europe.
TLDR
A major decline in the incidence of invasive disease in those countries that have introduced routine vaccination against serogroup C infection is demonstrated and case fatality was found to vary with clonal complex, suggesting that genotype can be a marker for hypervirulence. Expand
Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers.
TLDR
An outbreak of disease due to Neisseria meningitidis serogroup W135 (W135) occurred among pilgrims returning from the annual Islamic pilgrimage to Saudi Arabia and in their contacts in 2000 and 2001 and the risk that an un vaccinated household contact who had acquired W135 carriage would develop invasive meningococcal disease was estimated to be 1 case per 70 acquisitions. Expand
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.
TLDR
For unknown reasons, serogroup W135 achieved epidemic status, primarily among young children, and then largely disappeared over a short time period, emphasizing the need for ongoing surveillance and the potential benefit of vaccines that are protective across serogroups. Expand
...
1
2
3
4
...